查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566752

人造器官與醫療仿生市場：按類型、技術：2024-2033 年全球機會分析與產業預測

Artificial Vital Organs and Medical Bionics Market By Type (Artificial Organs, Medical Bionics) , By Technology (Mechanical, Electronic) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，人造器官和醫療仿生市場價值為474億美元，預計到2033年將達到990億美元，2024年至2033年的複合年成長率為7.6%。

人造器官是指當自然器官受損、發生故障或喪失功能時替代或模仿自然器官功能的醫療設備。這些設備旨在恢復失去的功能、增強人類能力並提高整體生活品質。另一方面，仿生植入是植入或附著在身體上以增強或恢復特定功能的電子或機械裝置。開拓基於仿生原理製造人體器官的生物人工器官製造技術，是人工生命器官和醫學仿生市場的重要里程碑。

儘管藥物、介入和手術治療取得了進步，但器官衰竭病例的驚人增加推動了全球人造器官和醫學仿生學市場的成長。嚴重的器官功能障礙不僅可能由受傷或疾病引起，也可能由視力或聽力喪失等非危及生命的疾病引起，這會降低生活品質並增加對人工重要器官的需求。此外，移植供體器官的短缺是全球市場的主要驅動力。根據器官移植網路 2024 年 3 月的統計數據，根據與美國衛生與公眾服務部簽訂的合約營運的器官移植網路 (UNOS) 已為全美約 103,223 名男性、女性和嬰兒提供了移植手術我在等候名單上。據同一消息來源稱，每天有 17 人在等待器官移植過程中死亡。此外，老年人口的快速成長是全球市場的主要驅動力。這是由於對人造器官解決方案的需求增加，因為老年人更容易因慢性疾病和功能障礙而出現器官衰竭，限制了他們執行日常家務的能力。根據世界衛生組織（WHO）的數據，2019年60歲以上的人口有10億人。預計到 2030 年，這一數字將增至 14 億，到 2050 年將增至 21 億，這可能會對市場成長做出重大貢獻。因此，所有這些因素都顯著促進了器官移植數量的增加。根據器官取得和移植網統計，2023年進行了超過4.6萬例器官移植。此外，對人工器官移植的認知和接受度不斷提高正在推動市場成長。導致創傷的事故案例不斷增加，以及導致截肢的糖尿病和周圍血管疾病盛行率的驚人上升，正在推動對醫療仿生學的需求。根據 ScienceDirect（世界領先的科學、技術和醫學研究資訊來源）2020 年發表的一項研究，美國每年約有 30,000 至 40,000 例平民因受傷而進行截肢手術。為了滿足截肢者不斷成長的需求，製造商正在專注於開發先進的義肢，這些義肢配備了感測器和致動器來模仿真實肢體的自然運動和功能，從而大大提高了活動能力。然而，人工器官移植和醫學仿生學的高成本、免疫排斥的風險以及倫理衝突是全球市場的主要阻礙因素。相反，人造器官的技術進步預計將為預測期內的市場擴張提供利潤豐厚的機會。例如，製造商專注於提高人造器官的功能、監測能力和整體有效性，因此正在將生物電子和數位健康技術融入其中，這將有望徹底改變移植產業。

人造器官和醫療仿生學市場按類型、技術、最終用戶和地區進行細分。根據類型，市場分為人造器官和醫學仿生學。人工器官又分為人工心臟、人工腎臟、人工肺臟等。醫學仿生學又分為整形外科仿生學和其他仿生學。在技​​術基礎上，市場分為機械市場和電子市場。依最終用戶分類，可分為醫院、門診手術中心等。從區域來看，我們對北美、歐洲、亞太地區和拉丁美洲/中東/非洲的市場進行了分析。

主要發現

按類型分類，預計到 2033 年，人造器官細分市場將佔據市場主導地位。

從技術角度來看，機械領域預計將在預測期內呈現最高成長。

對於最終用戶來說，醫院領域預計將在未來幾年受到高度關注。

按地區分類，北美是 2023 年的主要收益來源，在預測期內也可能主導市場。

可以使用此報告進行客製化（需要額外費用和時間表）

  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章人造器官與醫療仿生市場：依類型

  • 市場概況
  • 人造器官
    • 人工心臟
    • 人工腎
    • 人工肺
    • 其他
  • 醫學仿生學
    • 整形外科仿生學
    • 其他

第5章人造器官與醫療仿生市場：依技術分類

  • 市場概況
  • 機械的
  • 電子產品

第6章 人造器官與醫療仿生市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國人造器官與醫學仿生市場
    • 加拿大人造器官與醫學仿生市場
    • 墨西哥人造器官與醫療仿生市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國人造器官與醫學仿生市場
    • 德國人造器官與醫學仿生市場
    • 義大利人造器官與醫學仿生市場
    • 西班牙人造器官與醫學仿生市場
    • 英國人造器官與醫學仿生市場
    • 其他歐洲人造器官和醫學仿生市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國人造器官及醫學仿生市場
    • 日本人造器官及醫療仿生市場
    • 印度人造器官和醫學仿生市場
    • 韓國人造器官與醫學仿生市場
    • 澳洲人造器官與醫學仿生市場
    • 其他亞太人造器官及醫學仿生市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西人造器官與醫學仿生市場
    • 南非的人造器官和醫療仿生市場
    • 沙烏地阿拉伯的人造器官和醫療仿生市場
    • 其他拉丁美洲、中東和非洲人造器官和醫療仿生市場

第7章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第8章 公司簡介

  • SynCardia Systems LLC
  • Abbott Laboratories, Inc.
  • Cochlear Limited
  • Boston Scientific Corporation
  • Johnson And Johnson
  • Edwards Lifesciences Corporation
  • Zimmer Biomet Holding Inc.
  • Berlin Heart GmbH
  • Jarvik Heart, Inc.
  • Medtronic Plc.
簡介目錄
Product Code: A00270

The artificial vital organs and medical bionics market was valued at $47.4 billion in 2023, and is projected to reach $99.0 billion by 2033, growing at a CAGR of 7.6% from 2024 to 2033.

Artificial vital organs are medical devices that replace and mimic the functions of naturally occurring organs in individuals whose organs are damaged, dysfunctional, or impaired. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life. Bionic implants, on the other hand, are electronic or mechanical devices that are implanted within or attached to the body to enhance or restore specific functions. The development of bioartificial organ manufacturing technologies to produce human organs based on bionic principles acts as a significant milestone in the artificial vital organs and medical bionics market.

The growth of the global artificial vital organs and medical bionics market driven by alarming increase in cases of organ failure, despite advancements in pharmacological, interventional, and surgical therapies. Serious organ dysfunction is not only caused due injuries or diseases but also due to nonlife-threatening disabilities such as loss of eyesight or hearing ability, which decreases the quality of life, thereby augmenting the demand for artificial vital organs. Moreover, shortage of donor organs for transplantation acts as a key driving force of the global market. According to the March 2024 statistics of the Organ Procurement and Transplantation Network-operated under contract with the U.S. Department of Health and Human Services by the United Network for Organ Sharing (UNOS)-approximately 103,223 number of men, women, and children are on the national transplant waiting list. As per the same source, 17 individuals die each day waiting for an organ transplant. Furthermore, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fac that aged individuals are highly susceptible to chronic diseases and organ failure due to functional impairment that limit the ability to carry out day-to-day chores, thus boosting the demand for artificial organ solutions. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050, which is likely to significantly contribute toward the market growth. Thus, all these factors substantially contribute to increase in number of organ transplants carried out. The statistics derived from Organ Procurement and Transplantation Network suggest that more than 46,000 organ transplants were performed in 2023. In addition, rise in awareness and acceptance of artificial organ transplants is driving the growth of the market. Increase in cases of accidents causing traumatic injuries and alarming rise in prevalence of diabetes and peripheral vascular diseases that lead to amputations are driving the demand for medical bionics. According to a study published in 2020 in ScienceDirect-the world's leading source for scientific, technical, and medical research-approximately 30,000 to 40,000 civilian injury-related amputations are performed every year in the U.S. To meet the growing demand of amputees, manufacturers are focusing on the development of advanced prosthetic limbs equipped with sensors and actuators mimic the natural movement and functionality of real limbs, significantly improving mobility. However, high cost associated with artificial organ transplants and medical bionics, risk of immune rejection, and ethical conflicts act as the key deterrent factors of the global market. On the contrary, technological advancements in artificial vital organs are expected to offer remunerative opportunities for the expansion of the market during the forecast period. For instance, manufacturers are focusing on enhancing the functionality, monitoring capabilities, and overall effectiveness of artificial organs; thus, they are integrating bioelectronics and digital health technologies into artificial organs, which is expected to revolutionize the organ transplant industry in the coming years.

The artificial vital organs and medical bionics market is segmented into type, technology, end user, and region. Depending on type, the market is categorized into artificial organs and medical bionics. The artificial organs is further segmented into artificial heart, artificial kidney, artificial lungs, and others. The medical bionics is further segmented into orthopedic bionics and others. On the basis of technology, the market is bifurcated into mechanical and electronic. As per end user, it is classified into hospitals, ambulatory surgical centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the artificial organs segment is expected to dominate the market by 2033.

On the basis of technology, the mechanical segment is anticipated to exhibit highest growth during the forecast period.

Depending on end user, the hospital segment is projected to gain high prominence in the coming years.

Region wise, North America was the major revenue generator in 2023, and is likely to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial vital organs and medical bionics market include SynCardia Systems LLC, Abbott Laboratories, Inc., Cochlear Limited, Boston Scientific Corporation, Johnson & Johnson, Edwards Lifesciences Corporation, Zimmer Biomet Holding Inc., Berlin Heart GmbH, Jarvik Heart, Inc., and Medtronic Plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast

Key Market Segments

By Type

  • Artificial Organs
    • Artificial Heart
    • Artificial Kidney
    • Artificial Lungs
    • Others
  • Medical Bionics
    • Orthopedic Bionics
    • Others

By Technology

  • Mechanical
  • Electronic

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • SynCardia Systems LLC
    • Abbott Laboratories, Inc.
    • Cochlear Limited
    • Boston Scientific Corporation
    • Johnson & Johnson
    • Edwards Lifesciences Corporation
    • Zimmer Biomet Holding Inc.
    • Berlin Heart GmbH
    • Jarvik Heart, Inc.
    • Medtronic Plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Artificial Organs
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
    • 4.2.5. Artificial Heart
      • 4.2.5.1. Market Size and Forecast
    • 4.2.6. Artificial Kidney
      • 4.2.6.1. Market Size and Forecast
    • 4.2.7. Artificial Lungs
      • 4.2.7.1. Market Size and Forecast
    • 4.2.8. Others
      • 4.2.8.1. Market Size and Forecast
  • 4.3. Medical Bionics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
    • 4.3.5. Orthopedic Bionics
      • 4.3.5.1. Market Size and Forecast
    • 4.3.6. Others
      • 4.3.6.1. Market Size and Forecast

CHAPTER 5: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY TECHNOLOGY

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Technology
  • 5.2. Mechanical
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Electronic
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By Technology
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Artificial Vital Organs and Medical Bionics Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By Technology
    • 6.2.6. Canada Artificial Vital Organs and Medical Bionics Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By Technology
    • 6.2.7. Mexico Artificial Vital Organs and Medical Bionics Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By Technology
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By Technology
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. France Artificial Vital Organs and Medical Bionics Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By Technology
    • 6.3.6. Germany Artificial Vital Organs and Medical Bionics Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By Technology
    • 6.3.7. Italy Artificial Vital Organs and Medical Bionics Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By Technology
    • 6.3.8. Spain Artificial Vital Organs and Medical Bionics Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By Technology
    • 6.3.9. UK Artificial Vital Organs and Medical Bionics Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By Technology
    • 6.3.10. Rest of Europe Artificial Vital Organs and Medical Bionics Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By Technology
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By Technology
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Artificial Vital Organs and Medical Bionics Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By Technology
    • 6.4.6. Japan Artificial Vital Organs and Medical Bionics Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By Technology
    • 6.4.7. India Artificial Vital Organs and Medical Bionics Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By Technology
    • 6.4.8. South Korea Artificial Vital Organs and Medical Bionics Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By Technology
    • 6.4.9. Australia Artificial Vital Organs and Medical Bionics Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By Technology
    • 6.4.10. Rest of Asia-Pacific Artificial Vital Organs and Medical Bionics Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By Technology
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By Technology
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Artificial Vital Organs and Medical Bionics Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By Technology
    • 6.5.6. South Africa Artificial Vital Organs and Medical Bionics Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By Technology
    • 6.5.7. Saudi Arabia Artificial Vital Organs and Medical Bionics Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By Technology
    • 6.5.8. Rest of LAMEA Artificial Vital Organs and Medical Bionics Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By Technology

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. SynCardia Systems LLC
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Abbott Laboratories, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Cochlear Limited
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Boston Scientific Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Johnson And Johnson
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Edwards Lifesciences Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Zimmer Biomet Holding Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Berlin Heart GmbH
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Jarvik Heart, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Medtronic Plc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments